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Regulation of human mesangial cell growth in culture by thromboxane
A2 and prostacyclin. Elevated eicosanoid biosynthesis characterizes
certain forms of human and experimental glomerular proliferative
disease. Thromboxane A2 (TxA2) and other prostaglandins (PG) act
through specific receptors and mechanisms of intracellular signal trans-
duction in human mesangial cells. We studied the actions of U-466l9, a
TxA2 mimetic which stimulates mesangial phospholipase C, and of the
PGI2 analogue, Iloprost, a potent activator of adenylate cyclase, on
proliferation of cultured human mesangial cells. When applied alone to
quiescent cells, U-466l9 had only weak mitogenic activity, as assessed
by [3H]thymidine ([3H]-TdR) incorporation and cell counts. On the
other hand, addition of U-46619 10 minutes prior to stimulation of the
cells with Ito 17% fetal bovine serum (FBS) for 24 hours, potently and
dose-dependently inhibited FBS-stimulated [3H]-TdR incorporation.
Similarly, U-46619 inhibited the effects of 10 ng/ml platelet-derived
growth factor (PDGF), epidermal growth factor or basic fibroblast
growth factor on [3H]-TdR incorporation, by 55, 79 and 88%, respec-
tively. The effects of U-46619 were not mimicked by another stimulus of
phospholipase C, angiotensin II. Iloprost also inhibited FBS-activated
proliferation. Neither eicosanoid inhibited the rise of cytosolic Ca2
induced by FBS or PDGF. The actions of TxA2 and Iloprost in cultured
cells point to multiple functional interactions between eicosanoids and
growth factors in the control of mesangial cell proliferation.'
Thromboxane A2 (TxA2) and prostaglandin 12 (prostacyclin,
PGI2) are two major cyclo-oxygenase metabolites of arachi-
donic acid (AA), regulating vascular tone and interactions
between platelets and the vessel wall [1, 2]. While platelets and
leukocytes are the most abundant source of proaggregatory and
vasoconstrictor TxA2, endothelial cells release predominantly
PG!2. which inhibits platelet activation and is vasodilatory [1,
2]. Both TxA2 and PG!2 are produced in the human glomerular
microcirculation, albeit in relatively modest amounts [3—5]. On
the other hand, enhanced TxA2 production and/or PG biosyn-
thesis has been described in a number of inflammatory diseases
of the kidney, including human and experimental glomerulone-
phritis [6, 7], renal allograft rejection [8], ureteral obstruction
[9, 10], and renal vein occlusion [11], resulting from activation
of blood-borne cells and/or intrinsic glomerular cells [7]. In a
recent report describing patients with systemic lupus erythema-
tosus, a TxA2 receptor antagonist had beneficial effects on renal
hemodynamics, implying that this eicosanoid has in vivo ac-
tions on glomerular and vascular resistances [12]. The vasocon-
striction associated with these conditions correlates with the
elevated tissue levels of TxA2, and can be attenuated by means
of pharmacologic manipulations with TxA2 synthetase inhibi-
tors and receptor antagonists [7, 8, 12]. These effects of TxA2
are most likely mediated by contraction of vascular and glomer-
ular smooth muscle, that is mesangial cells [13]. We have also
recently identified potential mechanisms of signal transduction
for TxA2 in both rat and human mesangial cells, which upon
exposure to stable endoperoxide analogues (TxA2 mimetics)
display rapid, reversible increases of cytosolic free Ca2
([Ca2]), with cytosolic acidification, followed by long-lasting
resetting of basal [Ca2]1 and cytosolic alkalinization [14—16].
These ionic changes are related to phospholipase C activation,
with phosphoinositide breakdown and the release of intracellu-
lar second messengers such as inositol [1, 4, 5], trisphosphate
and, possibly, diacyiglycerol, the endogenous activator of pro-
tein kinase C [17, 18]. Structurally heterogeneous activators of
these signalling mechanisms trigger proliferation of a variety of
cell types, including mesangial cells [16, 17]. Moreover, PG
have opposite actions on cell proliferation, ranging from stim-
ulation of mitogenesis, with PGF2a and TxA2 [19, 20], to
inhibition, with POE2, P012 and a variety of synthetic ana-
logues [21—23]. In a companion study, we have identified a role
for PGF2a and PGI2 in the regulation of rat mesangial cell
proliferation in culture [24]. Since marked biologic differences
exist between cells of rat and human origin, as in the case of PG
synthesis and receptors for eicosanoids [14—16], we have now
focused our attention on the effects of TxA2 and PG!2 on
quiescent and cycling human mesangial cells. We also analyzed
the interactions between these vasoactive eicosanoids and
purified serum mitogens.
Methods
Cell culture
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Human mesangial cells were grown from glomerular ex-
plants, employing a modified technique [13, 15] by Striker and
Striker [25]. Glomeruli were isolated by sieving finely triturated
fragments of histologically normal renal cortex, obtained from
nephrectomies or kidneys not suitable for transplantation,
through 120 pm-mesh brass filters. The glomeruli were cot-
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lected on 75 pm-mesh nylon filters, decapsulated (>75%) by
forced flow through a 21-gauge needle, washed and incubated
for 25 minutes with 750 U mi-i collagenase Type IV (Wor-
thington Biochemical Corp. Freehold, New Jersey, USA) in
Ca2 and Mg2-free Hank's balanced salt solution. The result-
ing glomerular "cores" were then plated in Weymouth's or
RPM! 1640 media supplemented with 17% fetal bovine serum
(PBS; M.A. Bioproducts, Walkersville, Maryland, USA), 100
U . ml' penicillin, 100 g. m1 streptomycin (K.C. Biologi-
cal, Lenexa, Kansas), 5 sg . m1' insulin, 5 sg. mi transfer-
tin, 5 ng. m1' selenium (ITS Premix, Collaborative Research,
Lexington, Massachusetts, USA). The giomerular outgrowths
maintained at 37°C in a controlled 5% CO2 atmosphere yielded
virtually pure lines of mesangial cells within 7 to 10 days.
Subcultured cells were characterized and checked for purity by
previously described criteria [13, 15, 261. Four independent cell
lines were subcultured every four to six days and were used in
passages 1 to 12.
Cell pro! jferation assays
Human mesangial cells grown to confluence on 24-well dishes
were rendered quiescent by removal of FBS for 72 hours. Cell
viability was not affected by serum deprivation, as assessed by
morphology, estimation of the rate of detachment into the
medium and Trypan Blue vital dye exclusion. Serum depriva-
tion reduced methyl-[3HJ-thymidine ([3H]-TdR, 6.7 Ci
mmol, New England Nuclear, Boston, Massachusetts, USA)
incorporation to 2 to 5% of parallel monolayers maintained in
the presence of FBS (basal incorporation 320 26 cpm. well
4 hrs 1) Since massive contraction of superconfluent monolay-
ers (cell protein >100 pjg/well) occurred in initial experiments
within seconds of exposure to TxA2 mimetics, angiotensin II, or
FBS, occasionally with detachment, care was taken to with-
draw FBS shortly before reaching confluence. All experiments
have therefore been performed in slightly subconfluent mono-
layers. Phase-contrast microscopy was employed at the end of
each experiment to rule out any detachment in response to
serum or contractile agents. [3H]-TdR incorporation was reac-
tivated by readdition of 1 to 17% FBS, with a distinct increase
of incorporation at 18 hours, and a peak at 24 hours, as assessed
by pulsing the cells with [3H]-TdR every six hours up to 36
hours (see also Fig. 4 in Results). Stimulation of the cells with
test agents or their vehicle for 24 hours was therefore employed
in subsequent studies. The incubations were followed by re-
placement of the media with identical solutions supplemented
with 1 pCi . ml' [3H]-TdR for four hours. At the end of the
[3H]-TdR pulse, the medium was removed by aspiration, fol-
lowed by triplicate washes with phosphate buffered saline, pH
7.3. Each monolayer was then dissolved in 1 ml 0.1% sodium
dodecylsulphate (SDS) containing 1 mg . ml bovine serum
albumin (BSA; Calbiochem, La Jolla, California, USA) as a
carrier protein, and precipitated with 100 .d 100% trichloroace-
tic acid (TCA) for 30 minutes at 4°C. The TCA-precipitable
material was then pelleted by centrifugation at 3000 g at 4°C.
The supernate was collected, and a 500 d aliquot was counted
in a scintillation spectrophotometer after addition of 500 l
water and 9 ml scintillation fluid (New England Nuclear For-
mula 963). The pellet was redissolved in 500 td of 0.1% SDS and
counted. Counts in non-TCA precipitable material did not
exceed 5% of total radioactivity in each sample. All results were
expressed as percent increase of TCA-precipitable radioactivity
over duplicate/quadruplicate control, non-stimulated wells. Dif-
ferences were observed in the mitogenic potency of separate
batches of FBS and/or in the sensitivity of individual cell lines.
Each set of experiments was therefore performed employing
the same batch of FBS in various passages from two to three
cell lines, to minimize variability in fold-stimulation of [3H]-
TdR uptake. Cell protein was quite constant at 64.5 0.71
pjg/well (mean SE of S independent cultures).
Cell counts
Confluent cultures in 12-well dishes were trypsinized for one
minute at 37°C, followed by neutralization of trypsin with 1
mi/well of 17% FBS-supplemented RPM! 1640 medium. Com-
plete resuspension of the cells was verified by phase-contrast
microscopy, following gentle abrasion with a plastic scraper
(Costar, Cambridge, Massachusetts, USA). Duplicate counts
were performed by standard hemocytometry on triplicate wells
per condition, averaged and expressed as number of cells per
cm2 of growth surface. To ensure that release of the cells from
the plates due to intense contraction in response to TxA2
mimetics, vasoconstrictors or FBS did not affect total counts or
[3H]-TdR incorporation, cell counts were also performed di-
rectly in the incubation media and in pooled washings after
exposure to the agonists. Cell protein was measured by a
modification of Lowry's method [27].
Measurement of cytosolic free calcium ([Ca2 ])
[Ca2] was measured by a modification of a previously
described fluorometric technique in quiescent monolayers of
human cells loaded with the Ca2-sensitive intracellular probe
fura-2 ([14, 15, 27]. Briefly, cells were loaded with I M fura-2
acetoxymethylester (Molecular Probes, Eugene, Oregon, USA)
in serum-free RPM! 1640 for 40 minutes, followed by incubation
for 20 minutes in fura-2-free medium. Fluorescence of cells
grown on plastic Aclar coverslips (Allied Engineered Plastics,
Pottsville, Pennsylvania, USA) was monitored in a Perkin-
Elmer LS5B spectrofluorometer equipped with thermostated
cuvettes. The coverslips were placed vertically under continu-
ous stirring at 37°C in a modified Krebs-Henseleit solution
buffered with 20 mrvi HEPES and supplemented with 0.2%
BSA. Three hundred and forty/380 nm excitation wavelengths
were automatically alternated every five seconds. Emission
wavelength was set at 500 nm. Excitation/emission slits were
2.5 and 5 nm, respectively. Calibration of Ca2-dependent
fluorescence was obtained by addition of 15 to 40 /.LM ionomy-
cm, to saturate the dye to maximal fluorescence (max ratio,
Rmax), followed by 7.5 mst ethyleneglycol-bis-(/3-amino-
ethylether)N,N'-tetra-acetic acid (EGTA) plus 60mM Tris-HCI,
pH 10.5, to release Ca2 from fura-2 (minimal fluorescence,
Rmin). [Ca2}1 was then calculated according to the formula Kd
(F0/F)(R — Rmin/Rmax — R), in which F0 and F are the 380 nm
fluorescence excitations in the absence of Ca2 and at saturat-
ing Ca2, respectively. Kd of fura-2 for Ca2 is 224 n [28].
Autofluorescence of non-loaded monolayers was found to be
negligible and not affected by any of the experimental additions
or by the calibration procedure. Only FBS had intrinsic fluo-
rescence, requiring subtraction of background, simultaneously
measured in the absence of fura-2-loaded cells. The tracings in
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Fig. 1. Effects of 1% fetal bovine serum (FBS), 0.3 x 109M platelet-derived growth factor (PDGF), and 1.6 x 109M epidermal growth factor
(EGF) on ICa2]1 of cultured human mesangia! cells (A), Fluorescence monitoring of fura-2-loaded, confluent monolayers grown on plastic
coverslips, representative 340/500 nm excitation/emission tracings. Peak [Ca2] in response to 1% FBS or 10 ng/ml PDGF was 1754 161 and 314
23 n, respectively, mean SE of N =4 experiments for each condition. B. Cells pretreated for 3 mm with the TxA2 mimetic, U-46619, I zsi.
Peak [Ca2]1 in response to U-466l9 was 626 18 nM; FBS- and PDGF-stimulated [Ca2]1 after U-46619 was 1530 81 and 328 81 nM,
respectively (P = NSvs. control, unpaired (-tests). C. Cells pretreated for 3 mm with the PG!2 mimetic, Iloprost, I jiM. FBS- and PDGF-stimulated[Ca2] after Iloprost was 1617 258 and 395 48 n, respectively (P =NS vs. control, unpaired f-tests). Iloprost and EGF had no detectable
effect on [Ca2].
Figure 1 are reproductions of graphic displays in 340 nm
excitation mode.
Materials
U-46619 was purchased from Upjohn (Kalamazoo, Michigan,
USA). Iloprost was from Berlex (Cedar Knolls, New Jersey,
USA) and Schering AG (Berlin, FRG). SQ 27,427 was from
E.R. Squibb & Sons (Princeton, New Jersey, USA). Human
platelet purified platelet-derived growth factor (PDGF), epider-
mal growth factor (EGF), and basic fibroblast growth factor
(FGF) were purchased from Collaborative Research (Bedford,
Massachusetts, USA).
Statistical analysis
Dose-response curves of [3H]-TdR incorporation were ana-
lyzed by one-way analysis of variance on raw data. [3H]-TdR
incorporation curves in the presence of FBS or SQ 27,427 were
analyzed by two-way analysis of variance on raw data. Cell
counts on suspensions were analyzed by unpaired t-tests.
Results
Certain mitogens and vasoconstrictors, including PGF2 and
the endoperoxide analogue/TxA2-mimetic, U-46619, stimulate
mesangial cell phospholipase C, with rapid accumulation of
inositol 1 ,4,5-trisphosphate (InsP3) [15]. This results in a rise of
[Ca2]1, due to release of Ca2 from InsP3-sensitive stores, and
possibly to Ca2 influx through plasma membrane channels
(Fig. 1) [14, 15]. As shown in Figure 1, FBS induced a rapid,
transient rise of [Ca2] of human mesangial cells, followed by
a steady decrease towards pre-stimulation levels. Only low
concentrations of FBS could be tested (that is, <1%), because
of its intense fluorescence emission, which required back-
ground subtraction (Methods). The stimulation of [Ca2]1 by
FBS is most likely related to multiple vasoactive agents and
mitogens released by platelets and fetal tissue. One such
compound is PDGF, which typically increases [Ca2]1 of these
cells, although with distinctly slower kinetics (Fig. 1). Previous
work in our laboratory indicated that PGF2a, a phospholipase C
agonist, stimulates proliferation of rat mesangial cells in culture
[24]. Based on these results, we anticipated that TxA2, the most
potent eicosanoid-stimulating phospholipase C in human
mesangial cells [14, 15], would promote DNA synthesis similar
to PGF2 in rat cells. U-46619 did in fact significantly stimulate
[3H]-TdR incorporation in growth-arrested monolayers of hu-
man mesangial cells during 24 hour incubations in the presence
of insulin, to a maximum of about 40% above basal rates (Fig.
2). The response was dose-dependent and declined above
micromolar concentrations. The effects of U-46619 were com-
pletely abolished by the TxA2-receptor antagonist, SQ 27,427,
added at a tenfold molar excess 10 minutes prior to U-46619
(Fig. 2). For comparison, the mitogenic potency of maximal
concentrations of PDGF, EGF and FGF under the same strict
conditions, that is, lack of any mitogenic cofactor other than
insulin, ranged between 100 and 400% over basal [3H]-TdR
incorporation. Cell counts obtained in parallel monolayers
exposed to the same concentrations of U-466l9 confirmed a
modest, but significant growth-promoting activity of this ei-
cosanoid (Table 1). U-466l9 did not induce any significant
detachment of slightly subconfluent monolayers, as shown by
direct counts of cells in the incubation media (Table 1).
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Fig. 2. Stimulation of DNA synthesis by U-46619 in cultured human
mesangial cells, in the presence (A) or absence (•) ofa 10-fold molar
excess of the TxA2-receptor antagonist, SQ 27,427. Percent increases of
[3H]-thymidine incorporation after 24 hour incubations with U-46619
over parallel non-stimulated, quiescent cultures, mean SE of N = 6 to
8 experiments. P < 0.05 at >10-8 M, U-46619 vs. vehicle control,
one-way analysis of variance; P < 0.01, U-46619 + SQ 27,427 vs.
U-46619 alone, two-way analysis of variance.
Table 1. Effects of U-46619 and Iloprost on cultured human
mesangial cell number
Condition
Cells/cm2 culture
dish
Cells/mi in
supernates
Eicosanoids
Control 56,158 2,568 20,000 1,950
U-46619
1 LM 70,518 2,795 16,400 1,020
10 M 76,455 2,470 12,250 250
Iloprost
I /LM 55,314 1,543 19,700 1,400
10 M 58,250 2,870 21,500 1,950
Eicosanoids + FBS
Control 50,739 3,489 20,600 2,600
10% FBS 80,625 4,513 5,300 1,933
U-46619
100 nM + FBS 44,900 6,998
1 /LM + FBS 45,415 1612b 16,500 4,533
10 sM + FBS 41,331 3,614" 18,000 5,200
Iloprost
100 flM + FBS 67,750 4,510
1 LM + FBS 52,665 3,503a 19,500 3,500
10 LM + FBS 36,275 5315b 17,900 2,440
Cell counts in monolayers and incubation supernates after 24-hour
stimulation with either eicosanoid and/or 10% fetal bovine serum
(FBS).
P < 0.05 vs. control; a P < 0.05, b P < 0.01 vs. FBS, unpaired t-tests
on N = 4 to 12 experiments.
Since a number of vasoactive agents display "progression"
factor characteristics in cells primed with a "competence"
factor, we next examined whether U-46619 was capable of
magnifying the mitogenic activity of FBS or purified growth
factors possessing competence characteristics. Unexpectedly,
U-46619 displayed a clear, marked inhibitory activity on 1 to
17% FBS-induced [3H]-TdR incorporation into DNA and incre-
ments of cell counts (Fig. 3, Table 1). Inhibition of FBS-induced
mitogenesis was mediated by specific TxA2 receptors, since
% Fetal bovine serum
Fig. 3. Inhibition of I to 17% fetal bovine serum (FBS)-stimulated
DNA synthesis by U-46619, 10 nM-JO LM, in cultured human mesangial
cells. Symbols are: (•) FBS; (Lx) FBS + U-4619, 10 nM; (A) 100 nM;(0)1i; (0)10 M. Percent increases of [3H]-thymidine incorporation
after 24 hour incubations with FBS and U-466l9 over parallel non-
stimulated, quiescent cultures, mean SE of N = 8 experiments. * R
0.05, FBS + U-46619 vs. FBS, two-way analysis of variance on raw
data.
Table 2. Receptor specificity of the inhibitory effects of U-46619 on
fetal bovine serum (FBS)-induced DNA synthesis in cultured human
mesangial cells
Condition
[3H]-TdR incorporation
% of basal
10% FBS 2310 210
10% FBS + I LM U-466l9 1534 114k
10% FBS + 10 M SQ 27,427 2066 329
10% FBS + 10 M SQ 27,427 + 1 M U-46619 2436 198
The TxA2-receptor antagonist SQ 27,427 was added for 3 mm prior to
addition of U-466l9 or vehicle. Percent increases of [3H]-thymidine
([3H}-TdR) incorporation after 24 hour incubations with FBS and/or
U-46619/SQ 27,427 over parallel, non-stimulated quiescent cultures;
mean SE of N = 5 experiments.
a p < 0.05 vs. 10% FBS alone, one-way analysis of variance
pretreatment of the cells for three minutes with a tenfold molar
excess of the TxA2-receptor antagonist, SQ 27,427, abolished
the effect of U-46619 (Table 2). This is consistent with the
earlier studies employing U-46619 alone (Fig. 2). To understand
whether the effects of U-46619 were related to a temporal shift
in the peak incorporation of [3H]-TdR, we next exposed mono-
layers of cells to 1 tM U-46619 and 17% FBS for various lengths
of time, followed by [3H]-TdR pulsing for six hours (Fig. 4).
This procedure confirmed that FBS-stimulated reactivation of
DNA synthesis occurs between 18 and 24 hours, with peak
incorporation greater than 15-fold above quiescent levels, but
failed to show any delay of response in the presence of U-466l9,
which significantly inhibited [3H]-TdR incorporation through-
out the entire length of the study.
The effect of U-46619 was not due to inhibition of the [Ca2],
transient induced by FBS, as shown in Figure lB. Prior
stimulation of [Ca211 with U-46619 did not modify the duration
or amplitude of the FBS-stimulated elevation of [Ca2I1. This
indicates that phospholipase C activation by TxA2 does not
substantially alter the function of receptors for vasoactive
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Fig. 4. Time course of [3H]-thymidine incorporation in quiescent,
confluent mono/ayers of cultured human mesangial cells stimulated
with 17%fttal bovine serum (FBS) in the presence (A) or absence (•)
of! si U-46619for 6 to 36 hours. Six-hour pulse labelling at the end of
each incubation, cpm/well SE of N = 4 experiments. P < 0.05, FBS
vs. FBS + U-46619, two-way analysis of variance.
Table 3. Effects of angiote
serum (FBS)-stimulat
nsin II (ANG IL) on Ito 17% fetal bovine
ed DNA synthesis in cultured human
mesangial cells
[1H]-TdR incorporation
Condition % of basal
10% FBS 3518 492
+ ANG H
1 flM 3812 874
10 nM 3560 1047
100 flM 3092 324
1M 3642±58
17% FBS 5103 61
+ ANG II
1 flM 6618 1340
10 nM 5726 709
100 flM 5232 1298
I jsM 5599 271
Percent increases of [3H]-thymidine ([3H1-TdR) incorporation after 24
hour incubations with FBS or FBS and ANG II over parallel, non-
stimulated quiescent cultures; mean SE of N = 4 experiments.
101001 0
1flM nM LM1 1flM nM JLM M1
+ U-46619 + U-46619
Fig. 5. Inhibition of platelet-derived growth factor (PDGF, 0.1 to I
nM)-stimulated DNA synthesis (hatched bars) by U-46619, 10 nM to 10
M, in cultured human mesangial cells. Percent increases of E3HI-
thymidine incorporation after 24-hour incubations with PDGF and
U-466l9 over parallel non-stimulated, quiescent cultures, mean SE of
N = 6experiments. * P <0.05, **P<0.01 U-46619 + PDGF vs. PDGF
alone, one-way analysis of variance.
10 100 1 10
1flM nM LM M1
+ U-46619
Fig. 6. Inhibition of 10 ng/rnl epidermal growth factor (EGF) and
fibroblast growth factor (FGF)-stimulated DNA synthesis (hatched
bars) by U-46619, 10 nM to 10 /LM, in cultured human mesangial cells.
Percent increases of [3H]-thymidine incorporation after 24 hour incu-
bations with EGF/FGF and U-466l9 over parallel non-stimulated,
quiescent cultures, mean s of N = 6 experiments. * P <0.05 EGF
+ U-46619 vs. EGF alone, one-way analysis of variance.
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0agents and mitogens contained in FBS. That the inhibitory
actions of U-46619 are not mediated by short-term modifica-
tions of [Ca2]1 and/or pH is further shown by experiments
employing angiotensin II (ANG II), a vasoconstrictor peptide
that has nearly identical activity on these signal pathways in
human mesangial cells. ANG II, 1 flM to I M, had no inhibitory
effects on cell proliferation induced by 10 to 17% FBS (Table 3).
This points to a separate, as yet unknown intracellular signal
evoked by U-46619. U-46619 might activate adenylate cyclase
either directly or indirectly through stimulation of PGE2 or
PGI2, and thereby inhibit cellular proliferation. Although U-
466 19 stimulated intracellular cAMP in one human mesangial
cell line, no changes of cAMP were found in two other
mesangial cell lines (not shown). However, U-46619 inhibited
cellular proliferation in all three sets of human mesangial cells.
These results rule out an integral role for cAMP.
Consistent with the experiments with FBS, pretreatment of
the cells with U-46619 also inhibited the mitogenic activity of
various concentrations of PDGF, EGF and FGF, as shown in
Figures Sand 6. Again, prior treatment of the cells with U-46619
did not modify the early [Ca2]1 signal induced by PDGF, as
shown in Figure lB. EGF and FGF (not shown) had no effects
on [Ca2111.
The inhibitory effect of TxA2 on FBS-stimulated proliferation
was shared by another eicosanoid which selectively activates
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Fig. 7. Inhibition of 10% fetal bovine serum (FBS)-stimulated DNA
synthesis (hatched bar) by Iloprost in cultured human mesangial cells.
Percent increases of [3H]-thymidine incorporation after 24 hour incu-
bations with 10% FBS and Iloprost compared to parallel non-stimu-
lated, quiescent cultures, mean SE of N = 4 experiments. P < 0.05
Iloprost + FBS vs. FBS, one-way analysis of variance.
adenylate cyclase, namely the PG!2 analogue, Iloprost (Fig. 7).
As shown previously, this compound has no effect on [Ca2 1of
either rat or human mesangial cells (Fig. 1C) [14, 15]. Similar to
our previous data in rat cells, 100 nM to 10 /.tM Iloprost
dose-dependently inhibited the mitogenic effects of 10% FBS.
Its inhibitory action was confirmed by cell counts (Table 1), and
could not be related to cell detachment or modifications of the
[Ca2]1 response to FBS (Fig. IC).
Discussion
The present studies indicate that eicosanoids with different
signaling mechanisms modulate the growth of human mesangial
cells in culture. Albeit modestly stimulating [3H-TdR] incorpo-
ration when applied, in the presence of insulin, a TxA2 mimetic
displayed potent, dose-dependent inhibitory activity when
added with peptide mitogens such as PDGF, EGF, and FGF, or
to FBS. This action is similar to the antimitogenic effects of the
PG!2 analogue, Iloprost. In rat cells we and others have
observed that growth is regulated by a functional interplay
between mitogenic PGF2a and antiproliferative PGE2 and PG!2
[24, 29].
The effects of U-466l9 are not an artifact of altered [3H]-TdR
uptake or cell detachment, since: 1) we employed subeonfluent
monolayers which, as confirmed by phase-contrast microscopy,
did not detach in response to any contractile agent; 2) U-466l9
actually increased cell counts when applied alone to the mono-
layers, while significantly blunting the increments of cell counts
in FBS-treated monolayers; 3) U-46619 did not increase the
number of cells detached from the substrates in comparison to
control wells, alone or in the presence of FBS. Of note,
FBS-treated wells had a significantly lower number of detached
cells, most likely related to the attachment-promoting activity
of factors contained in serum. Once again, U-46619 did not
increase the number of detached cells above control incuba-
tions without FBS, although it apparently antagonized FBS-
promoted attachment.
TxA, mimetics have already been shown to be mitogenic in
cultured smooth muscle cells from hypertensive rats [20]. The
activity of the stable analogue of TxA2 employed in these recent
studies was remarkably similar to our present results in glomer-
ular cells, further indicating similarities between smooth muscle
and mesangial cells in culture [20, 30]. The potential biologic
significance of this finding is that increased tissue levels of TxA2
without concomitant release of platelet products may trigger
proliferation of mesangial cells, even in the absence of other
comitogens or competence factors. Such may be the case when
resident glomerular cells or monocytes are activated to release
TxA2 [6, 7, 9]. A different picture may characterize the simul-
taneous release of TxA2 and peptide growth factors, as in the
case of intraglomerular platelet activation, when the eicosanoid
may actually exert inhibitory actions on growth factor-induced
proliferation. Such conditions may occur in various forms of
chronic glomerular disease, in which elevated biosynthesis of
TxA2 and other eicosanoids is associated with extensive cell
proliferation. Class IV human lupus nephritis is an example of
diffuse proliferation, with or without necrotizing lesions, in
which TxA, (and possibly growth factors) may play a functional
role [12].
The mechanism(s) of this dual action of TxA2, and the
contrast with its major apparent signaling system, which has
previously been associated with mitogenesis [17—19], remain to
be delineated. In an effort to establish whether the interference
with growth factor-induced proliferation was related to the
Ca2-mobilizing effects of TxA2, we repeated a similar protocol
with ANG II, at a concentration that has nearly equipotent
effects on [Ca2'i and induces cytosolic alkalinization to levels
comparable to U-46619 (Menè P, Abboud HE, Dunn MJ,
unpublished results). ANG II did not inhibit FBS-induced
[3H]-TdR incorporation, making it unlikely that U-46619 inhib-
ited mesangial growth simply by increasing [Ca2] or pH1.
Moreover, Iloprost, a PG!2 mimetic that has no effects on
[Ca2]1, also inhibits mesangial cell proliferation, thus indicat-
ing that direct effects on [Ca2]1 or interference with agonist-
induced changes of [Ca2] are not required for inhibition of
mitogenesis.
The concept of eicosanoids as negative modulators of cell
growth is well supported by a body of literature in a number of
systems [19—23]. Mesenchymal cells such as vascular smooth
muscle cells release growth-inhibitory PGE2 upon stimulation
with mitogens such as interleukin- 1, whose proliferation effects
are enhanced by cyclo-oxygenase inhibition [22]. The antipro-
liferative activity of TxA2 and PG!2 in human mesangial cells
may reflect both a paracrine and an autacrine mechanism, with
the mesangium as a target for AA metabolites released by other
glomerular cell types or by platelets and leukocytes in glomer-
ular inflammation. This is likely to be the case for the interac-
tion between endothelial cells and mesangial cells, which share
large areas of contact without interposition of the glomerular
basement membrane [31, 321, and may communicate through
diffusible, labile mediators such as PGI2 or endothelial-derived
relaxing factors (EDRF) [35]. Of interest, many growth-inhibi-
tory compounds appear to act on cyclic nucleotides as intra-
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cellular mediators, as in the case of PGE2 and PGI2, which
stimulate cAMP [33, 34]. In general, there appears to exist a
complex of local mediators, or autacoids, released within the
glomerulus, that are capable of exerting a tonic inhibitory
influence on human mesangial cells. Eicosanoids and other
activators of mesangial cAMP are known to inhibit contractility
in culture [33, 36, 38]. We and others have described the role of
endogenous AA metabolites in modulating contraction of rat
cells in response to ANG II, platelet activating factor, or TxA2
[33, 36, 39]. The brisk contractility displayed by human mesan-
gial cells in culture may be related to deficient production of
relaxant prostanoids, as opposed to rat cells, which release
abundant PGE2 [3, 5, 40]. Similarly, intraglomerular PG and
TxA2 may oppose growth factor-induced proliferation of
mesangial cells, accounting for the low turnover of mesangial
cells in vivo, as assessed in normal rats by labelling with
[3H]-TdR [41]. The higher rates of growth of human cells
commonly observed in culture may reflect their deficient bio-
synthesis of PG, thus allowing for larger responses to the
mitogens contained in FBS or released by the mesangial cells,
as in the case of PDGF [26].
In conclusion, PG and/or TxA2 synthesis is enhanced in
inflammatory glomerular diseases associated with mesangial
proliferation [6, 7]. Based on the present findings, a modulatory
role of enhanced prostanoid biosynthesis may be envisioned, in
which the actions of peptide mitogens and platelet factors are
balanced by eicosanoids. Any failure of this compensatory
mechanism, as in the case of extensive damage of resident
glomerular cells, may result in deranged mesangial prolifera-
tion, with eventual progression to sclerosis.
Future work should aim at confirming these observations in
experimental and human disease. It should also be established
whether the effects of eicosanoids on mesangial growth reflect a
broader influence on biosynthetic functions, including mesan-
gial matrix, enzyme, cytokine and autacoid production. Such
knowledge would greatly enhance our understanding of the
pathophysiologic significance of glomerular AA metabolism.
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